Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services

No definition available.

Name:	tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices
Namespace Prefix:	tars_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services

+ References

No definition available.

+ Details

Name:	tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices
Namespace Prefix:	tars_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services

+ References

No definition available.

+ Details

Name:	tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices
Namespace Prefix:	tars_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Maximum Milestone Payment

+ References

No definition available.

+ Details

Name:	tars_CollaborativeArrangementMaximumMilestonePayment
Namespace Prefix:	tars_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront Payment

+ References

No definition available.

+ Details

Name:	tars_UpfrontPayment
Namespace Prefix:	tars_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tars_LianBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tars_ElancoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitment & Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)		1 Months Ended					2 Months Ended	3 Months Ended			6 Months Ended
	Sep. 03, 2020	Jun. 30, 2021	May 31, 2021	Apr. 30, 2021	Sep. 30, 2020	Jan. 31, 2019	May 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development								$ 7,204,000		$ 1,737,000	$ 23,465,000	$ 3,249,000
Common stock issued for license agreement, value									$ 5,494,000		5,494,000	$ 0
License agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development					$ 1,000,000.0	$ 1,000,000.0					$ 2,000,000.0
Common stock issued for license agreement (shares)					222,460
Common stock issued for license agreement, value					$ 3,100,000
Common stock issued for license agreement, share price (usd per share)		$ 14.0003						$ 14.0003			$ 14.0003
Additional shares to be issued upon 18-month anniversary of contract execution (shares)					187,500
Additional shares to be issued upon 18-month anniversary of contract execution, value	$ 5,500,000
Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)					$ 29.30
License agreement \| LianBio
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received		$ 10,000,000.0	$ 10,000,000.0	$ 15,000,000.0			$ 2,500,000
License agreement \| Elanco
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received							$ 25,000,000
License agreement \| Clinical milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		4,500,000				3,000,000.0		$ 4,500,000			$ 4,500,000
License agreement \| Commercial and sales milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		$ 77,000,000.0				$ 79,000,000.0		$ 77,000,000.0			$ 77,000,000.0